Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression

@article{Blasey2011EfficacyAS,
  title={Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression},
  author={C. Blasey and Thaddeus S Block and J. Belanoff and R. Roe},
  journal={Journal of Clinical Psychopharmacology},
  year={2011},
  volume={31},
  pages={436-440}
}
Open-label studies and randomized clinical trials have suggested that mifepristone may be effective for the treatment of major depression with psychotic features (psychotic depression). A recent study reported a correlation between mifepristone plasma concentration and clinical response. The current study aimed to evaluate the safety and efficacy of mifepristone and, secondarily, to test whether response was significantly greater among patients with mifepristone plasma concentrations above an a… Expand
Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response
TLDR
A combined analysis of all controlled phase 2 and 3 studies demonstrated meaningful efficacy for mifepristone in reducing psychotic symptoms with wide safety margins, followed by changes in adrenocorticotropin hormone and cortisol. Expand
Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression
TLDR
Although the primary end point was not met, patients who attained a mifepristone plasma level of 1637 ng/mL or greater demonstrated statistically significant reductions in psychotic symptoms compared with patients who received placebo starting on day 28, and showed nonsignificant, numeric superiority on Hamilton Rating Scale for Depression improvement. Expand
A Randomized Trial to Examine the Effect of Mifepristone on Neuropsychological Performance and Mood in Patients with Bipolar Depression
TLDR
It is demonstrated that brief treatment with mifepristone is associated with a sustained improvement in SWM, an effect that might be mediated by a persistent enhancement in hippocampal mineralocorticoid receptor function. Expand
Evaluation of Evidence of Adrenal Insufficiency in Trials of Normocortisolemic Patients Treated With Mifepristone
TLDR
This large pooled analysis of normocortisolemic patients without CS found no cases of AI and no differences between mifepristone therapy and placebo in the incidence of symptom combinations mimicking AI, even at the highest dose. Expand
Effects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men
TLDR
Systemic exposure to mifepristone increased following multiple doses of mifEPristone 600 mg daily plus ketoconazole 200 mg twice daily, and little to no increase in AEs occurred. Expand
The Treatment of Bipolar Depression: Current Status and Future Perspectives
TLDR
Ketamine represents a major breakthrough, producing rapid reductions in depressive symptoms even in cases of treatment-resistance, but challenges remain in how best to maintain response and reduce unwanted side effects. Expand
Metyrapone in treatment-resistant depression
TLDR
The most robust evidence for its antidepressant efficacy in depression comes from a double-blind, randomized, placebo-controlled study of augmentation of serotonergic antidepressants with metyrapone. Expand
Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties
TLDR
The aim of this article is to review published reports on the anti-progesterone and anti-glucocorticoid properties of mifepristone as a clinical agent and find new insight into systematically describing and evaluating the potential efficiency of m ifeprist one administrated in the field of endocrine and neuroendocrine, not only in obstetrics and gynecology. Expand
Future perspectives on the pharmacological management of depression
TLDR
There has been on-going debate about the ‘efficacy’ of antidepressants given a large placebo response in trial data, and recent studies are quoted that point to more effective ways in interpreting antidepressant randomized controlled trial data. Expand
Treatment Options for Psychotic Depression in Older People : Focused Literature review by New Zealand Psychogeriatric Team
Background: Psychotic major depressive disorder (PMDD) is complex with poor prognosis, reported in 15% to 25% of episodes with higher rates amongst older inpatients. There is little data on effectiveExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression
TLDR
A seven day course of mifepristone followed by usual treatment appears to be effective and well tolerated in the treatment of psychosis in PMD. Expand
A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.
TLDR
The association between increased mifepristone plasma concentration levels and greater clinical response, detected despite the site-by-treatment interaction, suggests that higher plasma levels may be needed for maximizing the probability of a positive response. Expand
Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
TLDR
The results suggest that short-term use of mifepristone may be effective in the treatment of PMD and may re-regulate the HPA axis. Expand
An open label trial of C-1073 (mifepristone) for psychotic major depression*
TLDR
These results suggest that short term use of GR antagonists may be effective in the treatment of psychotic major depression and that further blinded studies are warranted. Expand
Rapid Reversal of Psychotic Depression Using Mifepristone
TLDR
Preliminary results suggest that short-term use of GR antagonists may be effective in the treatment of psychotic major depression and that additional study, perhaps using higher doses or more treatment days, seems warranted. Expand
An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression.
TLDR
Mifepristone appears to be a useful intervention for psychotic depression, leading to significant improvements even after a 1-week course of administration, as well as issues related to its optimal dosing and to prediction of response. Expand
Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
TLDR
Mifepristone is generally well tolerated, and thus is an effective, appropriate, medical alternative to surgical termination of early pregnancy, and has as yet unexplored potential as a postcoital contraceptive and in oncology. Expand
Placebo response in studies of major depression: variable, substantial, and growing.
TLDR
The response to placebo in published trials of antidepressant medication for MDD is highly variable and often substantial and has increased significantly in recent years, as has the response to medication. Expand
DST studies in psychotic depression: a meta-analysis.
TLDR
Among patients with major depression, psychotic depression is the subtype that is most closely associated with nonsuppression of cortisol on the DST, andHypercortisolemia is usually present in psychotic depression and may be important in understanding the pathophysiology of this syndrome. Expand
Differential Response to Combined Treatment in Patients With Psychotic Versus Nonpsychotic Major Depression
TLDR
Patients with psychotic depression showed a poorer response in terms of depression severity at postoutpatient treatment and at 6-month follow-up compared with those with nonpsychotic depression. Expand
...
1
2
3
...